Stephen Marley Launches Plant-Based CBD Personal Care Line

Dec.14.2022
Stephen Marley Launches Plant-Based CBD Personal Care Line
Stephen Marley releases plant-based Kx Family Care, featuring CBD-infused Hair and Beard Oil, Pain Relief Balm, and more.

On Monday, Grammy-winning artist Stephen Marley launched a product line called Kx Family Care, which is a plant-based CBD personal care collection that utilizes the benefits of cannabis and other herbs traditionally used in Jamaica.


The debut series features limited holiday packages containing two products: a versatile hair and beard oil, and a pain relief balm both infused with full spectrum CBD oil, known for its anti-inflammatory, antibacterial, and antioxidant properties.


These two products also contain sunflower oil, vitamin E, and linoleic acid, which have antioxidants that help protect the skin from free radical damage and maintain its natural barrier. They also contain black seed oil, sapodilla fruit extracts, and star apple, which are widely used in Jamaican culture for their regenerative properties.


For example, Jamaican black castor oil comes from the seeds of the Nigella sativa plant, which is rich in antioxidants and offers various health benefits.


Kx Family Care is a natural progression for me, due to my passion for the cannabis plant and its various uses," said founder Stephen Marley. "This brand is authentic in every way, from the natural infusion of Jamaican plants in our products, to the eco-friendly wood and glass packaging we use. Our goal is centered on family, natural health, sustainability, and respect for the many uses of the cannabis plant.


Kx Family Care is the multi-generational personal-care product branch of Kaya Lifestyle, owned and operated by Marley. Kaya Lifestyle also hosts Kaya Fest, a music and education cannabis advocacy festival.


Marley joined the CEO and co-founder Shelly O'Neill to spend three years researching and developing a plant-based, multipurpose product designed specifically for busy families. Marley believes that marijuana is just like any other useful herb. "Marijuana is an herb, like mint or sage, that can cure many diseases and provide spiritual enlightenment," Marley told the cultural magazine in 2018.


The idea for Kx Family Care arose while O'Neill and Marley were working together at Kaya Fest, a world music festival organized by Marley to promote education surrounding the various uses of the cannabis plant. The term "Kaya" is a Jamaican slang word for herb, derived from the Caribbean English word "kayakiit," meaning a type of herb.


Experience Marley's cannabis products firsthand: Kx Family Care's pop-up store will be opening on specific dates during Stephen Marley's upcoming Old Soul Tour - Unplugged 2023.


We are pleased to introduce the first all-natural, cannabis-based personal care brand that is safe and effective for the entire family," said founder Stephen Marley. "We look forward to giving our customers a firsthand experience of the Kx Family Care pop-up store at the specific date of The Old Soul Tour - Unplugged in 2023.


The company stated that the US Food and Drug Administration (FDA) does not require basic safety testing on ingredients in personal care products. These products often contain toxic ingredients that can harm the skin and hair.


The company also maintains its commitment to the environment in its packaging.


Kx Family Care aims to utilize eco-friendly materials including hemp plastic to showcase the various uses of the cannabis plant and reduce plastic waste, according to its website. Inspired by Jamaica's nickname as the "land of wood and water," the company captures the essence by using biodegradable wood and glass in its packaging. Kx also spreads love by supporting different charitable organizations every quarter with a portion of its sales revenue.


Several siblings and family members of Marley have ventured into the CBD or cannabis business, including Ziggy and Damian.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
Philip Morris International's PMI Business Solutions Philippines has expanded its global business services hub in Makati and plans to add more than 80 positions. Established in 2021 primarily to provide finance and IT support to about 20 markets, the center now employs 519 professionals delivering roughly 600 services across 160 markets. Its functions now span finance, human resources, IT, commercial operations, data analytics, supply chain and project management. PMI says the hub's next phase will focus on AI-enabled and higher-value work. The company did not disclose the size or investment cost of the expansion.
Sep.24
Special Report|Virginia Vape Directory Shows Contrast Between Vuse and JUUL Pod Systems and CrossBar 20K, Loon Flavored Disposables
Special Report|Virginia Vape Directory Shows Contrast Between Vuse and JUUL Pod Systems and CrossBar 20K, Loon Flavored Disposables
A 2Firsts analysis of Virginia's liquid nicotine and vapor product certification directory identified 213 product records from 15 manufacturers. Companies associated with BAT, Altria, Imperial Brands, JTI and JUUL account for 127 entries. The directory also includes independent brands CrossBar 20K, Loon and Breeze. CrossBar advertises a 13mL disposable capable of up to 20,000 puffs, while Loon has 16 disposable entries featuring fruit, cooling and beverage-related flavors. Of all records, 120 are labeled as under FDA PMTA review. Virginia introduced revised penalties on October 1, 2026, including a minimum first-violation civil penalty of $5,000 per unlisted product, alongside new retail tobacco permitting requirements.
Regulations
Oct.30
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds American says nearly 183,000 U.S. retail outlets are under contract, with its Retail Marketing Plan Contract covering about 94% of company volume and requiring point-of-sale age verification. The company combines those contracts with We Card, TruAge, NACS-linked infrastructure and POS integration, while enhanced Vuse Pro retail rules add ID scanning, purchase limits and stronger underage-sales accountability. The initial Vuse Pro rollout targets about 50,000 stores. The system is taking shape as unauthorized vapor products remain dominant in parts of the U.S. market: a 2026 study estimated they accounted for 69.4% of tracked brick-and-mortar e-cigarette dollar sales in December 2025.
Special Report
Oct.15